Browse > Article

Inhibitory potency of Acetylcholinesterase and Amyloid beta(1-42) peptide aggregation to the Extracts of Enthusiasm Reducing herbals  

Kwon, Young-Ee (College of Pharmacy, Woosuk University)
Publication Information
Korean Journal of Pharmacognosy / v.38, no.4, 2007 , pp. 308-311 More about this Journal
Abstract
Inhibition of acetylcholinesterase and amyloid beta(1-42) peptide is good drug targets for Alzheimer's disease therapeutics. Among the twenty enthusiasm reducing herbals, the 70% methanol extracts (1 mg/ml) of Moutan Radicis Cortex and Forsythiae Fructus showed 91.5% and 85.3% about acethylcholinesterase inhibition, respectively. The extracts (1 mg/ml) of Coptidis Rhizoma and Paeoniae Radix Rubra showed more than 85% inhibition rate against amyloid beta (1-42) peptide aggregation. The neuroprotective effect of the extracts (1 mg/ml) of Moutan Radicis Cortex, Forsythiae Fructus and Paeoniae Radix Rubra showed 90.0%, 87.4% and 85.1% to compare with amyloid beta (1-42) peptide treated cells (IMR-32), respectively. Three herbs, Moutan Radicis Cortex, Forsythiae Fructus and Paeoniae Radix Rubra are promising candidates from natural products for development of Alzheimer's disease therapeutics.
Keywords
Alzheimer's disease; acetylcholinesterase; amyloid beta(1-42); Moutan Radicis Cortex; Gardeniae Fructus;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Lilienfeld S. (2002) Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8, 159   DOI   ScienceOn
2 Zarotsky V., Sramek J.J., Cutler N.R. (2003) Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60, 446
3 본초학 (2004) 영림사, 편집부, 777p
4 De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. (2001) A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry, 40, 10447   DOI   ScienceOn
5 Cottingham M.G., Voskuil J.L., Vaux D.J. (2003) The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry, 42, 10863   DOI   ScienceOn
6 Sugimoto H. (2001) Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. 1, 63   DOI   ScienceOn
7 Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. (2003) Alzheimer's disease- affected brain: presence of oligomeric A-beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA. 100, 10417
8 Pietrzik C., Behl C. (2005) Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. 86, 173   DOI   ScienceOn
9 Jann M.W. (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy, 20, 1   DOI   ScienceOn
10 Hollander E, Mohs R.C., Davis K.L. (1986) Cholinergic Approaches to the Treatment of Alzheimer's Disease. Br. Med. Bull. 142, 97
11 Khachaturian Z.S. (1985) Diagnosis of Alzhemier's Disease. Arch. Neurol. 42, 1097   DOI   ScienceOn
12 Barril X., Orozco M., Luque F.J. (2001) Towards improved acetylcholinesterase inhibitors: a structural and computational approach. Mini. Rev. Med. Chem. 1, 255   DOI   ScienceOn
13 Selkoe D.J. (1999) Translating Cell Biology into Therapeutic Advances in Alzhemier's Disease. Nature, 399, A23-A31   DOI   ScienceOn
14 Prous J., Rabasseda X., Castaner J. (1996) SDZ-ENA-713 Cognition Enhancer Acetylcholinesterase Inhibitor. Drugs Future, 19, 656
15 Silverberg G.D., Mayo M., Saul T., Carvalho J., McGuire D. (2004) Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert. Rev. Neurother. 4, 97   DOI   ScienceOn
16 Cottingham M.G., Hollinshead M.S., Vaux D.J. (2002) Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry, 41, 13539   DOI   ScienceOn
17 생약학 (2006) 동명사, 생약학교재편찬위원회, 523p, 420p
18 Kurz A. (1998) The therapeutic potential of tacrine. J. Neural Transm. Suppl. 54, 295